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Abstract 
In December 2019, an acute respiratory disease caused by novel species of coronavirus (SARS-CoV-2), 
emerged in China and has spread throughout the world. On 11th March 2020, the World Health 
Organization (WHO) officially declared coronavirus disease 19 (COVID-19) a pandemic, severe 
coronavirus-mediated human disease. Based on genomic and phylogenetic studies, SARS-CoV-2 might 
originate from bat coronaviruses and infects humans directly or through intermediate zoonotic hosts. 
However, the exact origin or the host intermediate remains unknown. Genetically, SARS-CoV-2 is 
similar to several existing coronaviruses, particularly SARS-CoV, but differs by silent and non-silent 
mutations. The virus uses different transmission routes and targets cells and tissues with 
angiotensin-converting enzyme 2 (ACE2) protein, which makes it contagious. COVID-19 shares both the 
main clinical features and excessive/dysregulated cell responses with the two previous Middle East 
respiratory syndrome coronavirus (MERS) and severe acute respiratory syndrome coronavirus (SARS) 
epidemics. In this review, we provide an update of the current knowledge on the COVID-19 pandemic. 
Gaining a deeper understanding of SARS-CoV-2 structure, transmission routes, and molecular responses, 
will assist in the prevention and control of COVID-19 outbreaks in the future. 
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Introduction 
The human community has experienced 
outbreaks and epidemics of many infectious diseases 
which are considered as major causes of human 
morbidity and mortality. Viral pathogens are known 
to cause outbreaks that have epidemic and pandemic 
potential. Several factors underlie the emergence of 
such diseases, including increasing population, 
increased domestic and global connectivity, social 
practices, prevalence of immunosuppressive diseases, 
change in agricultural practices such as mixed 
farming, and many other related environmental 
factors [1]. Climate changes and reduction in 
biodiversity may play a role by forcing species to 









seminatural habitats that may bring wild animals 
closer to humans [2]. Disturbance of natural 
ecosystems is reported to increase the transfer of 
disease from wild species to humans and is suggested 
to increase occurrences of neglected, forgotten and 
new human diseases [3]. It is well known that 
pathogen genomics vary considerably, thus, occurring 
genetic alterations have also been responsible for such 
outbreaks [4]. Although humanity has made 
meaningful progress in the battle against pathogens, 
the re-emergence of viral agents remains a great threat 
and challenge for the global health community [5]. 
About 60% of infectious diseases and 70% of 
emerging infections of humans are zoonotic in origin, 
with two-thirds originating in wildlife [6]. Over the 
last decades, several viral diseases had emerged in 
China, namely, those caused by the severe acute 
respiratory syndrome- (SARS-) coronavirus (CoV) 
and the H5N1, H1N1, and H7N9 viruses [7]. Recently, 
near the end of 2019, an outbreak of an ongoing viral 
pneumonia with unknown etiology emerged in the 
city of Wuhan, China. The infectious agent of this 
viral pneumonia was identified as the 7th member of 
human coronaviruses (2019-nCoV) [8]. On 11th 
February 2020, the World Health Organization 
(WHO) named the novel viral pneumonia 
“Coronavirus Disease 2019” (COVID-19), while the 
International Committee on Taxonomy of Viruses 
(ICTV) suggested this novel coronavirus will be 
named “SARS-CoV-2” due to the phylogenetic and 
taxonomic analysis of this novel coronavirus [9]. The 
SARS-CoV-2 emerged as a highly pathogenic and 
large-scale epidemic coronavirus compared to the 
severe acute respiratory syndrome coronavirus 
(SARS-CoV) in 2002 and Middle East respiratory 
syndrome coronavirus (MERS-CoV) in 2012. 
COVID-19 is characterized by a high infectivity 
during incubation and a time delay between really 
infected cases and daily observed number of 
confirmed cases [10]. The novel coronavirus is 
believed to be infectious during its incubation period, 
which is reported to be 3–7 days, at most 14 days, 
when no symptoms are shown in patients [11]. 
Environmental factors, particularly weather 
conditions, are suspected to favor emergence and 
spread of the outbreak. Both drought and cold, which 
characterized the 2019 winter in Wuhan [12], 
provided conducive environmental conditions for 
virus survival [13,14]. During the cold winter, 
air-dried virus particles are a dangerous form of virus, 
which survive for a long period of time in airflow [15]. 
In addition, cold conditions damper humans’ innate 
immunity by reducing blood supply and thus 
decreasing the provision of immune cells to the nasal 
mucosa. Low humidity can reduce the capacity of cilia 
cells in the airway to remove virus particles and 
secrete mucus as well as repair airway cells [16]. 
Many COVID-19 patients were potentially 
exposed to wildlife animals at the Huanan seafood 
whole sale market, Wuhan, China, where poultry, 
snake, bats, and other farm animals were also sold 
[17]. In such wildlife trade markets, animals known to 
transmit coronaviruses are crammed together under 
fetid conditions. Thus, humans might become 
unfortunate hosts for SARS-CoV-2 as a result of some 
inappropriate interactions with wildlife. Accumulated 
evidence suggests bats as the origin of the majority of 
emerging coronaviruses [18, 19,20,21]. Evolution and 
recombination of these different strains of bat viruses 
might lead to the creation of various SARS-CoVs 
capable of cross-species transmission and ultimate 
infection of human beings [22, 23, 24, 25]. Considering 
that the earliest COVID-19 patient reported no 
exposure at the seafood market, the suspected source 
of first virus infections [17], it becomes vital to identify 
the intermediate SARS-CoV-2 host to block 
interspecies transmission. Currently, the research on 
SARS-CoV-2 is in its primary stages. Based on current 
published evidence, this review summarizes 
SARS-CoV-2 origin, genetics, genomics, transmission 
routes, immune system responses and 
immunopathogenesis of COVID-19. 
Origin of COVID- 19 
Recently (at the time of writing this paper), the 
worldwide scientific community released full 
genomic sequences and several independent research 
groups have identified SARS-CoV-2 as a 
β-coronavirus. It is an enveloped virus containing a 
non-segmented, positive-sense RNA molecule 
[8,26,27]. In assigning the SARS-COV-2 to a taxonomic 
group, phylogenetic analysis of the complete viral 
genome revealed that the virus was most closely 
related (89.1% nucleotide similarity) to a group of 
SARS-like β-coronaviruses (β-CoVs) previously found 
in bats in China [28]. Sequencing and evolutionary 
analyses show that the bat was suspected as a natural 
reservoir host of the virus [19–21]. Indeed, the 
SARS-CoV-2 genome sequence is identical to those of 
bat CoVs, particularly to the RaTG13, with similarities 
from 96.2% to 99.9% [22,26,29–31]. SARS-CoV-2 might 
be transmitted from bats via unknown intermediate 
hosts to humans. Bats are the natural reservoir of a 
wide variety of CoVs, including SARS-CoV-like and 
MERS-CoV-like viruses [32–34]. The bat SARS-like 
coronavirus sequence is genetically more similar to 
the 2019-nCoV than other bat SARS-like coronavirus 
sequences, but is also more distant from sequences 
isolated in SARS and MERS coronaviruses [35]. A 
possible explanation is a past history of recombination 





in the β-coronavirus group [18]. Coronaviruses are 
characterized by a high rate of recombination, which 
may play a role in viral evolution and interspecies 
infections [36,23]. 
Given that bats were not available for sale in the 
seafood market in Wuhan and similar residues of 
virus receptor were observed in many species [24], 
alternative intermediate hosts, such as turtles, 
pangolin and snakes were proposed [23,24]. Usually, 
SARS-CoV and MERS-CoV infect intermediate hosts, 
such as civets or camels, before leaping to humans 
[37]. This fact indicates that SARS-CoV-2 was 
probably transmitted to humans from animals other 
than bats. Some studies suggested pangolin-CoV is 
the closest relative of SARS-CoV-2 [38,39]. On 24th 
October 2019, Liu and colleagues detected the 
existence of a SARS-CoV-like CoV in lung samples 
collected from two dead Malayan pangolins [38]. This 
discovery was made just prior to the COVID-19 
outbreak. Interestingly, Pangolin-CoV was composed 
of a 91.02 % identical genome to SARS-CoV-2 [39]. 
Notably, Paraskevis et al. [20] reported that the new 
coronavirus provides a new lineage for almost half of 
its genome, with no close genetic relationships to 
other viruses within the subgenus of sarbecovirus, 
rejecting the hypothesis of SARS-CoV-2 emergence as 
a result of a recent recombination event. Taken 
together, genomic and phylogenetic results indicate 
that the SARS-CoV-2 basal origin is still under debate. 
Figure 1 summarizes recent findings on the origin of 
SARS-CoV-2 and potential transmission routes. 
Immunopathogenesis 
Fever, cough, myalgia, or fatigue with abnormal 
lung scan findings are features of SARS-CoV-2 
infection. The less common symptoms are sputum 
production, headache, hemoptysis and diarrhea 
[17,40,41]. Few patients develop acute respiratory 
distress syndrome (ARDS), respiratory failure, 
multiple organ failure and even death [17]. The 
elderly and those with underlying disorders (i.e. 
hypertension, chronic obstructive pulmonary disease, 
diabetes, cardiovascular disease), are more likely to 
develop ARDS, cytokine storm, septic shock, 
metabolic acidosis, and coagulation dysfunction 
[11,17,42,43]. Several abnormalities have been 
observed including cellular immune deficiency, 
coagulation activation, myocardial injury, hepatic and 
kidney injury, and secondary bacterial infection 
[43].Of note, scientists reported that SARS-COV-2 
causes an inflammatory response in the lower airway, 
which may lead to lung injury [44,45]. Viral particles 
invade the respiratory mucosa, triggering immune 
responses and a “cytokine storm” closely related to 
the critical condition of COVID-19 patients [46]. 
COVID-19 symptoms showed differences in viral 
 
 
Figure 1. Origin of SARS-CoV-2 and potential transmission routes to humans. SARS-CoV-2 transmitted to humans from bats directly or by intermediate hosts such 
as rats, pangolins, snakes, and rats. The virus is spread among humans by different routes including droplets, aerosols, direct contact, and other potential routes such as urine, 
stool, and fecal swabs. Human organs expressingthe ACE2 receptor are targets for viral infection. Abbreviation: ACE2+, organs having ACE2 receptor. 





tropism compared to SARS-CoV [11,42,45], MERS- 
CoV [46] and influenza virus [47]. Innate immunity 
serves to slow viral infection before the adaptive 
immune response. IFN-γ secretion constitutes the first 
anti-viral defense barrier. In the case of SARS-CoV-2, 
IFN-γ secretion might be dampened by viral 
replication and subsequent inhibition of the adaptive 
immune response. Moreover, viral replication triggers 
hyper inflammatory conditions, leading to a high 
production of pro-inflammatory cytokines and 
chemokines, particularly by neutrophils and 
monocytes/macrophages [48–50]. Several plasma 
cytokines and chemokines were increased in 
COVID-19 patients, including IL-1, IL-2, IL-4, IL-7, 
IL-6, IL-10, IL-12, IL-13, IL-17, G-CSF, M-CSF, IP-10, 
MCP-1, MIP-1α, HGF, IFN-γ and TNF-α [17,24]. 
Normally, produced cytokines and chemokines play 
an anti-viral defense role through the recruitment of 
immune cells. However, in critical cases of COVID-19 
patients, a “cytokine storm” is reported and 
exacerbates immune reactions, initiating viral sepsis 
and ARDS. These exacerbations lead to death in some 
cases of elderly and those with underlying disorders 
[17]. 
Most patients have normal or decreased white 
blood cell counts, and lymphocytopenia [51]. 
However, in severe patients, the neutrophil count, 
D-dimer, blood urea and creatinine levels are 
significantly enhanced, while the lymphocyte counts 
are clearly reduced. The innate immune system 
recognizes viral ‘molecular patterns’ (such as double- 
stranded RNA) [52] and the adaptive immune 
systems kills virus-infected cells by means of T and B 
cells that produce pathogen-specific antibodies [53]. 
Regulated immune response inhibits virus 
replication, promotes virus clearance, induces tissue 
repair, and triggers a prolonged adaptive immune 
response against the viruses [54]. Figure 2 describes 
the mechanisms of host cell infection by SARS-CoV-2 
and gives a simplified schema of the immuno-
pathogenesis of COVID-19. 
 
 
Figure 2. Immune responses during SARS-CoV-2 infection. A. SARS-CoV-2 entry to host cell. Spike proteins on the surface of the coronavirus bind to 
angiotensin-converting enzyme 2 (ACE2) receptors on the surface of the target cell. Coronavirus genome replication and transcription takes place in the cytoplasmand involves 
coordinated processes of both continuous and discontinuous RNA synthesis. Assembly of viral proteins occurred in rough RE. Finally, the virus is released through exocytosis by 
Golgi. Abbreviations: S1, Spike 1; S2, Spike 2; ACE2, angiotensin-converting enzyme 2, RE, reticulum endoplasmic. B. COVID-19 immuno-pathogenesis. Infected cells present 
CoV antigens to T cells. This process leads to T cell activation and differentiation, including the production of cytokines associated with the different T cell subsets (Th1/Th17). 
Cytokines recruit lymphocytes and leukocytes to the site of infection. The adaptive immunity is involved through a subset of differentiated Tcells and activation of B and plasma 
cells that produce monoclonal antibodies. Activation of immune cells results in excessive productionof chemokines and other cytokines that induce a pro-inflammatory response 
and attract cells, such as neutrophils and macrophages, to sites of infection. In turn, these cells release injury molecules, such as matrix metalloproteinases and ROS. The 
“cytokine storm” represents the secretion of large quantities of immune mediators leading to more severe conditions. Regulated immune responses are crucial to clear the 
infection. Abbreviations: mAbs, Monoclonal Antibodies; Th, T helper; ROS, Reactive Oxygen Species. 





SARS-COV-2 genomics and variation 
Coronaviruses are single-stranded RNA viruses 
that belong to the order Nidovirales, family 
Coronaviridae, and subfamily Coronavirinae [54]. The 
family Coronavirinae is divided into four genera: α, β, 
γ, and δ. There are seven human coronaviruses: 229E 
(α-CoV), NL63 (α-CoV), OC43 (β- CoV), HKU1 
(β-CoV), MERS-CoV (β-CoV), SARS-CoV (β-CoV), 
and SARS-CoV-2 (β-CoV) [55]. The viral genome of 
SARS-COV-2 is composed of a positive-stranded 
RNA, and its structures vary considerably [8]. The 
complete genome of one strain of SARS-CoV-2, 
isolated from a COVID-19 pneumonia patient 
working in the Wuhan seafood market, is 29.9 
kilo-bases (kb) in size with 29891 nucleotides [56], 
encoding 9860 amino acids [57], while SARS and 
MERS-CoVs have RNA genomes of 27.9 kb and 30.1 
kb, respectively [58]. Similar to other β-CoVs, the 
SARS-CoV-2 genome contains two flanking 
untranslated regions (UTRs) and a variable number 
(8–13) of open reading frames (ORFs) [59]. Two-thirds 
of viral RNA, mainly located in the first ORF 
(ORF1a/b) translates two polyproteins, pp1a and 
pp1ab, and encodes 16 non-structural proteins (NSP). 
The remaining ORFs encode accessory and structural 
proteins [37]. The 2019-nCoV genome is arranged in 
the order of 5′-replicase (ORF1 /ab)-structural 
proteins [Spike (S)-Envelope (E)- Membrane 
(M)-Nucleocapsid (N)]−3′. The 5′- and 3′ -UTR 
sequences of 2019-nCoV, 265 and 358 nucleotides 
respectively in length, are similar to those of other 
β-CoVs, with 83.6% shared nucleotide identity. There 
are no remarkable differences between the ORFs and 
NSPS of 2019-nCoV with those of SARS-CoV [57]. The 
major distinction between 2019-nCoV and SARS-CoV 
is in spike S1 and ORF8, which were previously 
shown to be recombination hot spots [57]. In 
correlation with previous knowledge of CoVs 
genomics [60], the AT% was higher than GC% in 
SARS-CoV-2 [49]. In all of its structural genes, 
SARS-CoV-2 prefers pyrimidine rich codons to 
purines, and most high-frequency codons ended with 
A or T. The low-frequency codons ended with G or C 
[61]. This is in agreement with previous studies of 
CoVs [62]. SARS-CoV-2 structural proteins showed 
5-20 lower ENc values compared to SARS, bat SARS 
and MERS CoVs. This implies higher codon bias and 
higher gene expression efficiency of SARS-CoV-2 
structural proteins [61]. By meta-transcriptomic 
sequencing, another study showed that SARS-CoV-2 
exhibits some genomic and phylogenetic similarity to 
SARS-CoV, particularly in the S-glycoprotein gene 
and receptor-binding domain (RBD) [56]. Most 
genome-encoded proteins of SARS-CoV-2 are similar 
to SARS-CoVs [56]. Mutations in NSP2 and NSP3 play 
a role in the infectious capability and differentiation 
mechanism of SARS-CoV-2 [63]. 
Phylogenetic and genomic analyses from distinct 
countries suggest the newly-emerged SARS-CoV-2 
strains are closely related but are distinguished by 
both synonymous and non-synonymous mutations in 
different genomic locations [18,19,21,22,29,36,64-70]. 
Genome sequences of 2019-nCoV sampled from early 
cases were almost genetically identical [17,21], 
suggesting a very recent emergence of this virus in 
humans. The estimated genetic diversity of five newly 
sampled 2019-nCoV genomes was 0.000094 
substitutions per site with an estimated evolutionary 
rate of 0.0038 substitutions per site per year [65]. 
Accordingly, the newly identified 2019-nCoV 
sequences originated from the same isolate about 2 
years ago [64]. Evolutionary selection in the human 
hosts acts on SARS-COV-2 genomes, sometimes with 
parallel evolution events. Tang et al. [66] conducted a 
population genetic analysis of 103 SARS-CoV-2 
genomes and classified two prevalent evolving types 
of SARS-CoV-2: L type (~ 70%) and S type (~ 30%). 
Likewise, the complete genome analysis for the first 
cases of COVID-19 in Chile detected at least two 
different viral variants [67]. The new coronavirus 
could face selective pressures such as diversity in 
hosts, countries, weather, and other conditions. The 
phylogeographic patterns are potentially affected by 
distinctive migratory histories, founder events, and 
sample sizes [64]. This information contributes to 
monitoring the spread of the infection and the 
surveillance for eventual recombination or genome 
mutations. Population genetics-phylogenetics 
approach indicated that most sites in the viral ORFs 
evolved under strong to moderate purifying selection. 
Particularly, a non-negligible proportion of ORF8 
codons had evolved under very weak purifying 
selection or close to selective neutrality [30]. Positive 
selection was also detected in the receptor-binding 
motif (RBM) of the spike protein but most likely 
resulted from a recombination event that involved the 
BatCoV RaTG13 sequence [30]. The divergence of 
SARS-CoV-2 from BatCoV RaTG13 was accompanied 
by limited episodes of positive selection, suggesting 
the common ancestor of the two viruses was poised 
for human infection [30]. 
Homologous recombination contributes to the 
2019‐nCoV cross‐species transmission [23]. 
Homologous recombination is an important 
evolutionary force that occurs in many viruses, 
including Dengue virus [71], human immuno-
deficiency virus [72], hepatitis B virus [73], and 
hepatitis C virus [74]. A previous study suggested 
that recombination of SARS-CoV in the spike 





glycoprotein genes might have mediated the initial 
cross-species transmission event from bats to other 
mammals [25]. It is critical to determine the animal 
reservoir of the 2019‐nCoV to understand the 
molecular mechanism of its cross‐species spread. 
Findings shed a cautiously optimistic light on the 
possibility of finding effective treatment for this novel 
coronavirus, starting from already existing anti‐
β-coronaviridae compounds [29]. 
The process of infection in human 
In the past two decades, the 2019-nCoV is the 
third coronavirus to emerge in the human population 
after the SARS-CoV outbreak in 2002 [75] and the 
MERS-CoV outbreak in 2012 [76]. Full-genome 
sequence analysis of 2019-nCoV is different from both 
MERS-CoV and SARS-CoV that infect humans [8], but 
all are highly pathogenic zoonotic pathogens. Based 
on their phylogenetic relationships and genomic 
structures, human β-coronaviruses (SARS-CoV-2, 
SARS-CoV, and MERS-CoV) have many similarities 
but also have differences in their genomic and 
phenotypic structures that influence their 
pathogenesis. To date, no therapeutics or vaccines are 
approved against any human-infecting coronaviruses. 
Epidemiological investigations suggest SARS-CoV-2 
is highly transmissible in humans [77], especially in 
the elderly and people with underlying diseases [78]. 
The rapidly increasing number of cases and evidence 
of human-to-human transmission suggest the virus 
was more contagious than SARS-CoV and MERS-CoV 
[79,80]. WHO estimates, the basic reproduction 
number (R0), as 1.4 to 2.5 less than SARS (2 to 5); but, 
this number can grow if the pandemic is not 
controlled by applying quarantine and isolation 
strategies [21]. The high affinity between ACE2 and 
2019-nCoV spike protein also suggests the population 
with a higher expression of ACE2 might be more 
susceptible to 2019-nCoV [81]. The SARS-CoV first 
emerged in China in 2002 and then spread to 37 
countries/territories in 2003 and caused a 
travel-related global outbreak with a 9.6% mortality 
rate [82]. There is evidence that SARS-CoV originated 
in bats in China and reached humans after jumping 
from an intermediate host, the civet (Pagumalarvata) 
[83]. MERS-CoV, discovered in 2012 in the Middle 
East [84], is endemic in dromedary camels, from 
which it can be transmitted to humans [20]. The MERS 
epidemic is ongoing, and as of December 2019, 2468 
cases have been reported [85]. Less virulent 
coronavirus species cause common colds in humans 
with relatively mild symptoms [86]. Some 
coronaviruses are strictly host-specific, while others 
can be found in a range of hosts [87]. 
Genetically, SARS-CoV-2 was less similar to 
SARS-CoV (about 79%) and MERS-CoV (about 50%) 
[88,89]. The arrangement of nucleocapsid protein (N), 
envelope protein (E), and membrane protein (M) 
among β-coronaviruses are different. Both 
SARS-CoV-2 and SARS-CoV bind to human ACE2 
[90] and use transmembrane protease serine 2 
(TMPRSS2) to complete cell entry and infection 
[89,91]. The SARS-COV-2 spike protein has a furin 
cleavage site in the S1/S2 junction, different from 
SARS-CoV and other closely related bat viruses [92]. 
This has implications for viral entry routes. The 
TMPRSS2 also contributes to the S-protein priming of 
2019-nCoV, indicating that the TMPRSS2 inhibitor 
might constitute a treatment option [89]. There are 
many similarities between SARS-CoV-2 and the 
original SARS-CoV [93], and their S proteins share 
76.47% identity [93,94]. A total of 53 unique S proteins 
were selected and their structures modeled according 
to different subtypes of CoVs, including 2019-nCoV 
(WH-Human_1), 3 SARS strains, 2 β-CoV strains, and 
47 strains from other CoVs. S proteins of 2019-nCoV 
and SARS strains share high structural similarity with 
a root-mean-square deviation of 1.21 Å [94]. Wan et al. 
[94] reported that residue 394 (glutamine) in the 
SARS-CoV-2 RBD, corresponding to residue 479 in 
SARS-CoV [95], can be recognized by the critical 
lysine 31 on the human ACE2 receptor. A highly 
similar epitope was identified computationally 
between the 2019-nCoV and SARS-CoV on the 
binding site of the S proteins to the human ACE2 
receptor [55]. Further analysis even suggested 
SARS-CoV-2 recognizes human ACE2 more 
efficiently than SARS-CoV, increasing the ability of 
SARS-CoV-2 to transmit from person to person [94]. 
Potential transmission routes of 
SARS-CoV-2 
As an emerging acute respiratory infectious 
disease, COVID-19 primarily spreads through the 
respiratory tract by droplets, respiratory secretions, 
saliva, and direct contact for a low infective dose 
[42,96]. The common transmission routes of novel 
coronavirus include direct transmission (cough, 
sneeze, droplet inhalation transmission) and contact 
transmission with oral, nasal, and eye mucous 
membranes [97]. Since 2019-nCoV can be passed 
directly from person to person by respiratory 
droplets, emerging evidence suggests it may also be 
transmitted through contact and fomites [98]. The fact 
that SARS-CoV-2 can infect the human gut epithelium 
has important implications for fecal–oral transmission 
and containment of viral spread [99]. The ACE2 
receptor is abundantly present throughout the 
respiratory tract, as well as in the epithelial cells of 
salivary gland ducts that have been demonstrated to 





be early targets of SARS-CoV [100]. Both SARS-CoV 
and SARS-Cov-2 may have much faster replication 
rates than other coronaviruses infect humans [94] . 
The 2019-nCoV can produce aerosols, droplets, or 
particulate matter with high viral loads that increase 
the viability time of the virus in various environments 
[100]. After reaching the recipients, the fast replication 
viruses have a higher chance of successful infection 
[100]. Of note, a report of one case of 2019-nCoV 
infection in Germany indicates that transmission of 
the virus may also occur through contact with 
asymptomatic patients [97]. In fact, the asymptomatic 
incubation period for individuals infected with 
2019-nCoV has been reported to be ~1–14 days. Thus, 
those without symptoms can spread the virus [101]. 
On 10th February 2020, SARS-CoV-2 was isolated 
from fecal swabs from a severe pneumonia patient in 
China [102], indicating the possibility of multiple 
routes of transmission. In addition, a recent pilot 
experiment showed that 4 out of 62 stool specimens 
tested positive for 2019-nCoV, and another four 
patients in a separate cohort who tested positive from 
rectal swabs also had 2019-nCoV detected in the 
gastrointestinal tract, saliva, or urine [30]. Thus, in 
addition to the respiratory droplets and direct contact, 
fecal–oral transmission might also be a route of 
transmission for 2019-nCoV [40]. Remarkably, the 
ACE2 protein presents abundantly on enterocytes in 
the small intestine [103], which may contribute to this 
route of infection and disease manifestations. 
However, the aerosol transmission route and the 
fecal–oral transmission routes still need to be further 
studied. 
Analysis of conjunctival samples from confirmed 
and suspected cases of 2019-nCoV suggests eye 
exposure may provide an effective way for the virus 
to enter the body [104], and that ocular surfaces may 
be a potential target for SARS-CoV-2 invasion [98]. 
However, other studies do not fully support this 
assumption [105]. ACE2 is mainly expressed in 
posterior tissues of the eye, such as the retina and the 
retinal pigment epithelium, not in the human 
conjunctival and corneal epithelium [106]. 
Furthermore, tears are constantly renewed by the 
lacrimal drainage system. Therefore, the virus enters 
the tears through droplets, which may pass through 
the naso-lacrimal ducts and then into the respiratory 
tract [88]. 
Asymptomatic patients can spread SARS-CoV-2 
with high efficiency in noninfectious disease settings 
such as otolaryngology, which is a high-risk specialty 
as it closely contacts the upper respiratory tract 
mucous, secretions, droplets and aerosols during 
procedures and surgery [107, 108]. Otolaryngologists 
have been infected with COVID-19 at higher rates 
than other specialties [107]. Of note, pathogens can be 
transmitted in dental settings through inhalation of 
airborne microorganisms that can remain suspended 
in the air for long periods [109]. Direct contact with 
blood, oral fluids, contact of conjunctival, nasal, or 
oral mucosa with droplets and aerosols containing 
microorganisms generated from an infected 
individual [110], and indirect contact with 
contaminated instruments and/or environmental 
surfaces [111], can rapidly spread viral pathogens. 
Dental studies show that many dental procedures and 
contaminated dental instruments or environmental 
surfaces provide possible routes to the spread of 
viruses [112,113]. Human coronaviruses such as 
SARS-CoV, MERS-CoV, or endemic human 
coronaviruses (HCoV) can persist on surfaces like 
metal, glass, or plastic for up to a couple of days [114], 
making contaminated surfaces in healthcare settings a 
potential source of coronavirus transmission. 
Key viral factors 
The coronaviral genome encodes four structural 
proteins, namely, S protein, N protein, M2 protein, 
and E protein [54,115]. The N protein interacts with 
the viral RNA to form the ribo-nucleoprotein [116]. 
The E protein conducts ion channel actions and 
contributes to virions assembly [117]. Coronavirus 
entry to host cells is a multi-step process involving 
several distinct domains in the surface glycoprotein 
spike (S). The S protein, a trimeric class I fusion 
protein, exists in a metastable prefusion conformation 
that undergoes a substantial structural rearrangement 
to fuse the viral membrane with the host cell 
membrane [118,119]. The S protein contains the RBD 
and mediates virus attachment to the cell surface, 
receptor engagement, protease processing, and 
membrane fusion, facilitating viral entry into host 
cells [120–124]. The virion S-glycoprotein on the 
coronavirus surface can attach to the ACE2 receptor 
on the surface of human cells [125]. The S proteins 
mutate and gain capability to recognize host receptors 
across species [118,126]. For many CoVs, spike is 
cleaved at the boundary between the S1 and S2 
subunits [121]. For SARS-CoV, the cleavage of the 
trimer S protein is triggered by the cell 
surface-associated TMPRSS2 [127] and cathepsin 
[128]. To engage a host cell receptor, the RBD of S1 
undergoes hinge-like conformational movements that 
transiently hide or expose the determinants of 
receptor binding [129]. The RBD for SARS-CoV-2 has 
residues and motifs found in all three clades but 
forms a distinct clade [94]. Receptor binding 
destabilizes the pre-fusion trimer, resulting in 
shedding of the S1 subunit and transition of the S2 
subunit to a stable post-fusion conformation [130]. 





After membrane fusion, the RNA viral genome is 
released into the cytoplasm, and the uncoated RNA 
translates two polyproteins, pp1a and pp1ab [130], 
which encode non-structural proteins and form a 
replication-transcription complex (RTC) in double- 
membrane vesicles. RTCs replicate and synthesize a 
nested set of subgenomic RNAs [131], which encode 
accessory proteins and structural proteins. Mediated 
by the endoplasmic reticulum (ER) and the Golgi, 
newly formed genomic RNA, nucleocapsid proteins, 
and envelope glycoproteins assemble and form viral 
particle buds [131]. 
SARS-CoV-2 and ACE2 
The ACE2 protein is enriched in the enterocytes 
in the small intestine and the renal tubules, as well as 
in the lung alveolar epithelial cells, the heart cells, the 
arterial smooth muscle cells, and the gastrointestinal 
system [133,134]. This protein is best known for 
cleaving several peptides within the renin–
angiotensin system and other substrates [135]. ACE2 
protein is rare in circulation, but widely expressed in 
organs, such as kidneys, the gastrointestinal tract, and 
at relatively lower levels, the lungs [136]. Recently, 
based on scRNA-seq datasets, Zou et al. [105] 
constructed a 2019-nCoV infection-related risk map of 
different organs including nasal mucosa, respiratory 
tract, bronchus, and lung. They found that pulmonary 
AT2 cells and respiratory epithelial cells exhibited 
high ACE2 expression. Similarly, Zhao et al. [81] 
demonstrated that 83% of ACE2-expressing cells were 
alveolar epithelial type II cells (AECII), suggesting 
these cells can serve as a reservoir for viral invasion. 
In addition, gene ontology enrichment analysis 
showed ACE2-expressing AECII have high levels of 
multiple viral process-related genes, including 
regulatory genes for viral processes, viral life cycle, 
viral assembly, and viral genome replication [81], this 
implies that the ACE2-expressing AECII facilitates 
coronaviral replication in the lung. Taken together, 
these data suggest that the respiratory tract should be 
considered as a vulnerable target to SARS-CoV-2 
infection. 
For the human heart, more than 7.5% of 
myocardial cells demonstrate positive ACE2 
expression, implying that the heart could be at high 
risk of 2019-nCoV infection, especially in the presence 
of viremia [105]. Moreover, myocardial infarction may 
increase ACE2 expression in heart, thereby suggesting 
that ACE2 plays an important role in cardiac injury 
[137]. Interestingly, the digestive system, including 
the esophagus, stomach, ileum, and liver, showed 
extremely high ACE2 expression in epithelial cells 
[81,105,138,139]. In addition, proximal tubule cells in 
the kidney and bladder urothelial cells express ACE2, 
making kidney and bladder a sat risk for infection 
[103,105,140]. Taken together, ACE2 tissue 
distribution in different organs could explain the 
multi-organ dysfunction and the non-respiratory 
symptoms observed in some 2019-nCoV pneumonia 
patients and may help to explain the increased 
human-to-human transmissibility of this virus [94]. 
The ACE2 extracellular domain has been 
demonstrated as a receptor for the S protein of 
SARS-CoV [141], and recently, for the SARS-CoV-2 
[26]. Therefore, accumulated evidence suggests that, 
similar to SARS-CoV, SARS-CoV-2 uses ACE2 as its 
host receptor [79,94,105,142] but with higher affinity 
than does SARS-CoV [79,94,105,143]. The similarity 
with SARS-CoV is critical because ACE2 is a 
functional SARS-CoV receptor in vitro [144] and in 
vivo [145], and this may have implications in 
therapeutics. Of note, the SARS-CoV-2 does not use 
other coronavirus receptors such as aminopeptidaseN 
and dipeptidylpeptidase 4 [31]. 
During infection, the cleavage of the spike 
protein required for cell-to-cell fusion depends on 
both cell type and virus strain [146]. Spike protein is 
proteolytically cleaved by the cellular enzyme furin 
into S1 and S2 subunits during intracellular 
processing [123,147]. The second cleavage S29 exposes 
the fusion peptide and is thus necessary for viral entry 
[108], whereas S1 contains the RBD, which directly 
binds to the peptidase domain (PD) of ACE2 [34]. The 
ectodomain of the SARS-CoV-2 S protein binds to the 
PD of ACE2 with a dissociation constant (Kd) 
of~15nM [126]. The RBD is recognized by the 
extracellular peptidase domain of ACE2 mainly 
through polar residues [148]. SARS-CoV-2 and 
SARS-CoV RBDs show high similarities [94]. 
However, a number of sequence variations and 
conformational deviations were found [148]. A single 
N501T mutation (corresponding to the S487T 
mutation in SARS-CoV) may significantly enhance the 
binding affinity between the 2019-nCoV RBD and 
human ACE2 [94]. Of note, for SARS-CoV 
pathogenesis, ACE2 is not only the entry receptor of 
the virus but also has a protective role during acute 
lung injury in a mouse model [145]. By binding ACE2, 
SARS-CoV leads to the downregulation of ACE2 
expression and might therefore negate the protective 
effect of ACE2 [145,149]. Human and non-human 
primates share the identity sequences in the regions 
and residues, implying that ACE2 from non-human 
primates may recognize 2019-nCoV and mediate its 
infection [42]. As a result, non-human primates may 
be susceptible to 2019-nCoV and serve as animal 
models for antiviral research or intermediate hosts for 
cross-species transmission. 






Figure 3. Phylogenetic analysis of full-length genomes of SARS-CoV-2 and representative sequences of genera Alpha, Beta, Delta-, and 
Gammacoronaviruses. A. Phylogenetic analysis of SARS-CoV-2 with Alpha-, Beta-, Delta- and Gammacoronaviruses full-genomes. Colored boxes denote genera. Purple: 
Gammacoronavirus. Green: Deltacoronavirus. Blue: Alphacoronavirus. Orange: Betacoronavirus. SARS-CoV-2 strains are collapsed in one branch under the Betacoronaviruses. 
Tree data were collated from updated sources published until June 4th, 2020 [26,151,152]. Abbreviations: CoV, coronavirus; MHV murine hepatitis virus; PHEV porcine 
hemagglutinating encephalomyelitis virus; IBV infectious bronchitis virus; MERS Middle East respiratory syndrome; SARS severe acute respiratory syndrome. B. Phylogenetic 
analysis of SARS-CoV-2 full-genomes. The collapsed SARS-CoV-2 branch from A is shown in full. 
 
Analysis of coding-region variants using the 
GTEx database in ACE2 and of the expression 
quantitative trait loci (eQTL) variants, which may 
affect the expression of ACE2, support the existence of 
ACE2 mutants resistant to S-protein binding of 
coronavirus in different populations [150]. East Asian 
populations have much higher AFs in eQTLvariants 
associated with higher ACE2 expression in tissues, 
suggesting different susceptibility or response to 
SARS-CoV-2 compared to other populations under 
similar conditions [150]. A recent single-cell 
RNA-sequencing (RNA-seq) analysis indicated that 
Asian males may have higher expression of ACE2 
[78]. The genetic basis of ACE2 expression and 
function in different populations is still largely 
unknown. Increasing understanding of potential 
functional variants in ACE2 among populations 
requires further epidemiological investigations of 
SARS-CoV-2. 
Comparison of SARS-CoV-2 sequences 
with other coronaviruses 
Animals have a critical role in COVID-19 
outbreak onset and evolution and may act as the virus 
reservoir. The exact origin of SARS-CoV-2 remains 
unknown; therefore, phylogenetic analyses are 
established to find the animal virus reservoir. A 
phylogenetic analysis comparing the genomes of 
SARS-CoV-2 with other coronaviruses is shown in 
Figure 3 [26,151,152]. Nucleocapsid (NC) protein, 
which is highly conserved and immunogenic, is 
commonly targeted in studies aimed at developing 
alternative diagnostic tools [153]. Multiple alignments 





of the whole protein sequences highlight a very high 
homology between the NC sequence of SARS-CoV-2 
and bat RaTG13 CoV [154]. Tilocca et al showed that 
some epitopes are shared among a wider range of 
coronaviruses, while other epitope sequences are 
more conserved among the most related specimens 
[154]. Based on the high-homology between the Spike 
protein epitopes of taxonomically-related 
coronaviruses, Tilocca et al. hypothesized that past 
contact with infected dogs shield humans against the 
circulating SARS-CoV-2 [155]. By using the Immune 
Epitope Database and Analysis Resource (IEDB), 
Grifoni et al. found that SARS-CoV has high sequence 
similarity to SARS-CoV-2, and is the best 
characterized coronavirus in terms of epitope 
responses. Multiple specific regions with high 
homology to the SARS-CoV in addition to a priori 
potential B and T cell epitopes for SARS-CoV-2 have 
been [156]. Authors suggest these regions are 
promising targets for immune recognition of 
SARS-CoV-2 and can facilitate effective vaccine 
design against this virus [156]. 
Compared with other CoV species, bovine CoV 
is the genetically closest counterpart to human 
coronaviruses [157,158]. A high similarity was 
observed between bovine CoV, canine respiratory 
coronavirus (CRCoV) and human coronavirus OC43 
(HCoV-OC43) [159]. More investigations to assess the 
transmission rate of the bovine and canine respiratory 
coronaviruses to humans are needed. Homology 
modelling showed that 2019-nCoV had a similar RBD 
structure to that of SARS-CoV, despite amino acid 
variation at some key residues [26]. Lu et al. showed 
that 2019-nCoV was related (with 88% identity) to two 
bat-derived severe acute respiratory syndrome 
(SARS)-like coronaviruses, bat-SL-CoVZC45 and 
bat-SL-CoVZXC21 and more distant from SARS-CoV 
(about 79%) and MERS-CoV (about 50%). However, 
they also revealed that S gene of 2019-nCoV had the 
lowest sequence identity with bat-SL-CoVZC45 and 
bat-SLCoVZXC21, at only around 75% [26]. Zhou et 
al. demonstrated that the novel virus has 96.2% 
similarity to a bat SARS-related Coronavirus 
(SARSr-CoV; RaTG13 (MN996532.1) [31]. Proteins 
from SARS and SARS-CoV-2 were treated as 
homologous: identity value > 65%, query coverage, 
>95% [160]. SARS-CoV-2 has been found to be more 
distant in relation to SARS-CoV (79%) and MERS-CoV 
(50%) [161]. Anand et al. found that all sequences 
showed ~99.98% similarity in the nucleotide 
sequences, implying a relationship between the 
currently circulating viruses and suggesting a recent 
shift to humans [161]. 
Comparison of the novel coronavirus 
Wuhan-Hu-1 sequence with that of the closely related 
human SARS-CoV S strain Tor2 sequence, revealed 
76% homology [162]. The S1 RBD was less conserved 
(64% identity) than the S2 fusion domain (90% 
identity). The identity between SARS-CoV-2 and 
SARS-CoV at the S protein amino acid level was 76%, 
and phylogenetic analyses grouped SARS-CoV-2 in 
the lineage B of the Betacoronavirus genus, closely 
related to SARS-CoV, as well as to other CoVs 
originating in bats [162]. The relatively high degree of 
sequence identity for the RBD is consistent with the 
view that SARS-CoV-2, like SARS-CoV, may use 
ACE2 as its host cell receptor [162]. The amino acid 
homology of the modeled S proteins in comparison to 
the template SARS-CoV S was ~ 71% for all the 
Bat-CoV S, with the exception of the LYRa3 S, which 
shares a homology of 84.7% with the template S. 
Overall, all the modeled S proteins shared a similar 
folding pattern in comparison to SARS-CoV S and 
both S1 and S2 domains showed a uniform 
organization [162]. The S protein amino acid identity 
among the Bat-CoV ranged between 75.3% and 96.7%, 
with LYRa3 and RaTG13 S proteins having the lowest 
and highest identity to SARS-CoV-2, respectively 
[162]. The tertiary structure of the polyprotein isolate 
SARS-CoV-2_HKU-SZ-001_2020 had 98.94 % identity 
with SARS-Coronavirus NSP12 bound to NSP7 and 
NSP8 co-factors [163]. 
The analysis of fifteen sequences of SARS-CoV-2 
S sequences obtained from NCBI and GISAID from 
China and various export locations worldwide along 
with representative members of lineages A–D 
betacoronaviruses showed that all SARS-CoV-2 S 
sequences clustered very closely with bat SARS-like 
sequences, with the closest matching sequence 
corresponding to Bat-SL-RaTG13 [162]. Pairwise 
comparison between SARS-CoV-2 S protein and that 
of BatCoV-RaTG13 and representative sequences 
from Guangxi pangolin (2017, abbreviated GX here) 
and Guangdong pangolin (2019, abbreviated GD) 
confirm that overall BatCoV-RaTG13 had the highest 
identity: 97% overall, 96% and 100% for S1 and S2, 
respectively [162]. The analysis revealed that pangolin 
S protein sequences are more divergent overall (92% 
identity for GX and 89% identity for GD), with most of 
the divergence concentrating in the S1 domain. the 
RBD domain of the GD domain was confirmed to be 
remarkably well conserved compared to SARS-CoV-2 
(97% identity compared to 87% identity for GX 
pangolin and 89% for BatCoV-RaTG13) [162]. Another 
study showed that he homology of SARS-CoV-2 with 
the Bat coronavirus isolate RaTG13 strain (MN996532) 
was 96%, but has no more than 80% homology with 
other isolates of bat SARS‐like coronavirus [164]. 
Zhang et al. showed that some pangolin CoV 
genes show higher amino acid sequence identity to 





SARS-CoV-2 than to RaTG13 genes [39]. The RBD 
region within the S1 which is conserved between 
Pangolin CoV and SARS-CoV2, is phylogenetically 
closer to pangolin-CoV than RaTG13 pointing 
potential similarity in their pathogenic properties [39]. 
At the whole genome sequence level, pangolin CoV 
and SARSr-CoV RaTG13 show 91.02% and 96.2% 
similarity with SARS-CoV-2 but the S1 subunit of 
spike protein of pangolin CoV is more closely related 
to SARS-CoV-2 than SARSr-CoV RaTG13. Other 
studies have shown that the homology with a 
coronavirus strain isolated from pangolin was 99%, 
suggesting that SARS‐CoV‐2 might have originated 
from bat and pangolin might have served as the 
intermediate host between bat and human [165]. The 
genetic analysis of the currently circulating strains of 
the pandemic have shown 99.98-100% similarity in 
their genomes, implying a recent shift to humans 
[161]. Description of the epitopes distribution over the 
viral population might provide valuable information 
driving future researches aimed at setting efficient 
prophylactic strategies and/or the design of tool 
capable of differential diagnosis on the basis of 
serological tests. 
Sequence alignment analysis provides evidence 
of high sequence homology for some of the 
investigated proteins. In addition, homology 
modelling of structural epitope mapping revealed a 
potential immunogenic value for specific sequences 
scoring a lower identity with SARS-CoV-2 
nucleocapsid proteins [154]. Accumulated evidence 
provide a molecular structural rationale for a 
potential role in conferring protection from 
SARS-CoV-2 infection and identifying potential 
candidates for the development of diagnostic tools. 
Further experimental studies are desired for a 
confidential evaluation of the postulated hypotheses. 
Finally, further studies employing purified forms of 
the spike proteins and/or its epitopes are needed and 
should be evaluated carefully. 
Current diagnostic tools for COVID-19 
Currently, severeral diagnostic tests for 
coronavirus include RT-PCR, real-time reverse 
transcription PCR (rRT-PCR), reverse transcription 
loop-mediated isothermal amplification, as well as 
real-time RT-LAMP are used [166, 167]. RT-LAMP 
was used to detect MERS-CoV, it is highly specific 
and has similar sensitivity to rRT-PCR [168,169]. 
The China National Health Commission, 
laboratory examinations established that 
nasopharyngeal and oropharyngeal swab tests, have 
become a standard assessment for diagnosis of 
COVID-19 infection [170]. Two one-step quantitative 
RT-PCR (qRT-PCR) assays were developed to detect 
two different regions (ORF1b and N) of the 
SARS-CoV-2 genome, allowing for earlier 
identification of patients [170]. Later, three novel 
RT-PCR assays targeting the RNA-dependent RNA 
polymerase (RdRp)/helicase (Hel), spike (S), and 
nucleocapsid (N) genes of SARS-CoV-2 were 
developed. Among them, the COVID-19-RdRp/Hel 
assay had the lowest limit of detection in vitro [171]. 
The SARS-CoV E gene assay was more sensitive than 
the RdRp gene assay combined with the one-step 
RT-PCR system [172]. The E gene PCR was sufficient 
to diagnose a SARS-CoV-2 infection but the RdRp 
protocol was recommended to confirm a positive 
result [173,174]. The overall positive rate of RT-PCR 
detection of SARS-CoV-2 infection in 4880 cases from 
one hospital in Wuhan was 38% [175]. In a series of 51 
patients with confirmed COVID-19 infection, 71% 
patients were RT-PCR positive at the first time of 
testing of throat swab or sputum samples [176]. The 
RT-PCR results usually become positive after several 
days (2-8 days) [177]. Chest CT scans can be used to 
assess the severity of COVID- 19. Despite negative 
RT-PCR results, COVID-19 infection should be 
diagnosed with typical chest computerized 
tomography (CT) characteristics for patients suffering 
from fever, sore throat, fatigue, coughing or dyspnea 
[178]. Of 1014 patients, 59% had positive RT-PCR 
results, and 88% had positive chest CT scans [179]. 
Assessment of imaging features combined with 
clinical and laboratory findings could facilitate early 
diagnosis of COVID-19 pneumonia [180,181,182]. The 
detection of nucleic acid in the nasal and throat swab 
sampling or other respiratory tract samplings by 
real-time PCR and further confirmed by 
next-generation sequencing is qualified as the most 
qualified method to diagnosis of COVID-19. Some 
published sequences comparisons of SARS-CoV-2 
with other coronaviruses are presented in Table 1. 
Potential therapeutics for COVID-19 
Until the writing of this paper, there is no current 
evidence from randomized controlled trials (RCTs) to 
recommend any specific anti-SARS-CoV-2 treatment 
for COVID-19 infection. Antiviral drugs and systemic 
corticosteroid treatment commonly used for influenza 
virus including neuraminidase inhibitors, ganciclovir, 
acyclovir, and ribavirin, as well as methyl-
prednisolone [183] are invalid for COVID-19. 
However, other viral drugs are found to treat cases of 
COVID-19 such as remdesivir which has been 
reported to successfully treat the first case of 
COVID-19 in the US [184]. Based on the experience 
accumulated from the SARS and MERS outbreaks, 
lopinavir (LPV) is a potential treatment option for 
COVID- 19, LPV inhibits the protease activity of 





coronavirus in vitro and in animal studies [185]. 
Ribavirin, a guanosine analogue used to treat several 
virus infections, showed promising results in a 
MERS-CoV rhesus macaque model [186] and in 
SARS-CoV-2 RNA-dependent RNA polymerase 
(RdRp) model [187]. These features increase its 
potential as an antiviral against SARS-CoV-2 [188]. 
Nelfinavir was predicted to be a potential inhibitor of 
SARS-CoV-2 main protease [188]. The other 
promising antiviral drugs include nitazoxanide, 
favipiravir, nafamostat, and so on [189]. 
Chloroquine is a repurposed drug with great 
potential to treat COVID-19. It is a widely-used 
antimalarial and autoimmune disease drug that has 
been reported to be a potential broad-spectrum 
antiviral drug [190, 191, 192], and it has been used to 
treat malaria for many years [193]. The chloroquine 
antiviral proprieties are investigated, it can inhibit 
pH-dependent steps of the replication of several 
viruses [194, 195], it has immunomodulatory effects, 
suppressing the production/release of TNF-α and 
IL-6, works as a novel class of autophagy inhibitor 
[196], which may interfere with viral infection and 
replication. Several studies have found that 
chloroquine interfered with the glycosylation of 
cellular receptors of SARS-CoV [195] and functioned 
at both entry and at post-entry stages of the 
COVID-19 infection in Vero E6 cells [197]. 
Chloroquine was effective in more than 100 
COVID-19 patients in terms of reduction of 
exacerbation of pneumonia, duration of symptoms 
and delay of viral clearance, all in the absence of 
severe side effects [198]. Therefore, it has been 
included in the recommendations for the prevention 
and treatment of COVID-19 pneumonia [198]. 
Hydroxychloroquine was found to be more potent 
than chloroquine Using physiologically-based 
pharmacokinetic (PBPK) models in SARS-CoV-2- 
infected Vero cells [199]. Taken together, both 
chloroquine and hydroxychloroquine have immuno-
modulatory effects and can suppress the immune 
response [200], and may be used in prophylaxis as 
well as curative treatment for individuals exposed to 
SARS-CoV-2 [201]. The optimal dosage of chloroquine 
for SARS-CoV-2 will need to be assessed in future 
trials [201], in addition to the age of the patient and 
the clinical presentation or stage of the disease [202]. 
In a study of 41 COVID-19 patients, 21% received 
corticosteroids, which could suppress lung 
inflammation [203], in respect to administered dose 
depending on disease severity [203]. However, the 
clinical outcomes of coronavirus and similar 
outbreaks do not support the use of corticosteroids. In 
a retrospective observational study, 309 MERS 
patients given corticosteroids were more likely to 
require mechanical ventilation, vasopressors, and 
renal replacement therapy [204]. Overall, there are 
many reasons to prevent treatment of patients with 
COVID-19 infection with corticosteroids, and such 
treatment may be harmful [205]. Alternatively, 
Chinese clinicians combined Chinese and Western 
medicine treatment including lopinavir/ritonavir, 
arbidol, and Shufeng Jiedu Capsule (SFJDC, a 
traditional Chinese medicine) and gained significant 
improvement in pneumonia associated symptoms in 
Shanghai Public Health Clinical Center, China [206]. 
 
Table 1. Sequences similarities expressed as % identity, between SARS-CoV-2 and other coronaviruses 
Other Coronaviruses Bat SARS Pangolin Camel MERS- Dromedarius Bovine H-Enteric Canine Avian 
Epitopes of SARS-CoV-2 nucleocapsid  
KHWPQIAQ; FAPSASAFF 100 100 100 78.571 78.571 78.571 52.941 52.941 52.941 - 
AQFAPSA; SAFFGMSR 100 100 71.429 78.571 78.571 78.571 52.941 52.941 52.941 - 
AQFAPSA; SAFFGMSR 100 100 100 71.429 71.429 71.429 63.636 63.636 63.636 58.333 
PKGFYAEG; SRGGSQASSR 100 100 100 61.111 61.111 61.111 61.111 48 48 100 
QFAPSASAF; FGMSRIGM 100 100 100 81.818 81.818 81.818 50 50 50 53.846 
QLPQGTTLPKGF; YAEGSRGGSQ 100 100 100 61.111 61.111 61.111 66.667 66.667 66.667 100 
YNVTQAFGR; RGPEQTQGNF 100 100 100 63.158 63.158 63.158 58.824 58.824 58.824 - 
SARS CoV-2 spike protein  
424–437 - - - - - - 80 80 80 - 
447–458 - - - - - - 75 - 75 - 
754–764 - - - - - - 83.33 83.33 83.33 - 
789–799 - - - - - - 57.14 57.14 57.14 - 
1139–1152 - - - - - - 70 100 70 - 
SARS CoV-2 Spike protein (GI QHR63290)  
AGO98871 - - - - - - 38.42 - - - 
QAY30020 - - - - - - - - 37.68 - 
ACJ35486 - - - - - - - 37.68 - - 
ACT10865 - - - - - - 31.23 - - - 
SARS-CoV-2_HKU-SZ-001_2020  - 98.94  - - - - - - - - 
SARS-CoV-2 strain - - 99 - - - - - - - 
SARS-CoV-2 (Wuhan-Hu-1)  
ORF1ab 95 86 - - 50 - - - - - 





Other Coronaviruses Bat SARS Pangolin Camel MERS- Dromedarius Bovine H-Enteric Canine Avian 
S 80 76 - - 30 - - - - - 
ORF3a 91 72 - - - - - - - - 
E 100 94 - - 36 - - - - - 
M 98 90 - - 42 - - - - - 
ORF6 93 68 - - - - - - - - 
ORF7a 88 85 - - - - - - - - 
ORF8 94 40 - - - - - - - - 
N 94 90 - - 48 - - - - - 
 
 
The development of vaccines and therapeutic 
antibodies against COVID-19 has important 
implications. The majority of the vaccines being 
developed for coronaviruses target the spike 
glycoprotein. The cross-reactivity of anti-SARS-CoV 
antibodies with the COVID-19 spike protein was 
assessed because SARS-CoV- 2 and SARS-CoV show a 
relatively high identity of the receptor-binding 
domain (RBD). The SARS-CoV-specific human 
monoclonal antibody CR3022 binds potently with the 
COVID-19 RBD [207]. However, other SARS-CoV 
RBD-directed antibodies 230, m396 and 80R cannot 
bind to the COVID-19 RBD. Thus, Wrapp et al. 
suggest that CR3022 may be a potential therapeutic 
candidate, alone or in combination with other 
neutralizing antibodies, for the prevention and 
treatment of COVID-19 infections [208]. Monoclonal 
antibodies can only recognize a single antigen 
epitope, which limits their use in the treatment of 
COVID-19. Applying monoclonal antibodies for new 
pathogens to clinical practice requires time. 
Alternatively, convalescent plasma has been 
suggested to treat COVID-19, the method was used 
early after symptom onset in the treatment of SARS, 
and the pooled odds of mortality following treatment 
was reduced compared with placebo or no therapy 
(odds ratio, 0.25) [209]. Now, the structure of 
SARS-CoV-2 is revealed allowing to the development 
of medical countermeasures and optimization 
vaccination strategies.  
Future directions 
The emerging pneumonia, COVID-19, caused by 
SARS-CoV-2, is a contagious pandemic. At the time of 
writing, the pandemic is still ongoing, with no 
available treatment. To battle this pandemic and be 
prepared for future outbreaks, it is crucial to 
understand its pathogenesis. SARS-CoV-2 exhibits 
strong infectivity but reduced virulence compared to 
SARS and MERS-CoVs. Fortunately, the scientific 
community has made progress in the characterization 
of the novel coronavirus and is working extensively 
on therapies and vaccines. Phylogenetic analyses 
suggest a bat origin of 2019-nCoV, but, considering 
the widespread distribution of SARS-CoVs in natural 
reservoirs, such as bats, camels, and pangolins, 
further research is needed to find novel intermediate 
hosts and block interspecies transmission. The 
genomic structure of the newly emerged coronavirus 
is evolutionary and may be under selective pressure 
with several mutations and homologous 
recombination. 2019-nCoV also potentially recognizes 
ACE2 from a diversity of animal species, implicating 
these animal species as possible intermediate hosts or 
animal models for 2019-nCoV infections. These results 
provide insights into the receptor usage, cell entry, 
host cell infectivity, and animal origin of 2019-nCoV. 
Furthermore, epidemic surveillance and preventive 
measures against SARS-CoV-2 will be enhanced. 
Structural studies on ACE2 receptor complexes with 
2019-nCoV spike protein will contribute to 
understanding cross-species receptor usage of this 
novel coronavirus. In vitro studies will be useful for 
investigating how SARS-CoV-2 modifies gene 
expression in primary target cells, such as 
macrophages, dendritic cells, lymphocytes, and 
pulmonary epithelial cells. Animal models will allow 
investigators to determine the relationship between 
viral load and disease outcome, as well as to evaluate 
the role of infection and immune dysfunction in the 
disease process. Gained knowledge will facilitate the 
development of specific therapies designed to 
minimize pulmonary disease and optimize the 
anti-SARS-CoV-2 immune response. The striking 
structural similarity and sequence conservation 
among the SARS-CoV-2 S and SARS-CoV S 
glycoproteins emphasize the close relationship 
between these two viruses, which both recognize 
human ACE2 to enter target cells. This resemblance is 
further strengthened by the finding that SARS-CoV 
spike elicited polyclonal antibodies responses, 
potently neutralizing SARS-CoV-2 spike-mediated 
entry into cells [80]. The SARS-CoV-2 RBD binds to 
ACE2 with a higher affinity than does the SARS-CoV 
RBD. Thus, potent SARS-CoV-specific neutralizing 
antibodies that target the receptor binding site of 
SARS-CoV failed to bind 2019-nCoV S protein, 
indicating that it is necessary to develop novel 
monoclonal antibodies that could bind specifically to 
the 2019-nCoV RBD [210]. Other scientists indicate 
that the soluble ACE2 may act as a competitive 
interceptor of SARS-CoV and other coronaviruses by 





preventing binding of the viral particle to ACE2 [211]. 
Indeed, in vitro studies showed SARS-CoV replication 
was blocked by a soluble form of ACE2 in a monkey 
kidney cell line [212,213]. Moreover, ACE2 fused to 
the Fc portion of immunoglobulin has just been 
reported to neutralize SARS-CoV-2 in vitro [214]. In 
this context, soluble recombinant human ACE2 
protein could actually be beneficial as a novel biologic 
therapeutic to combat or limit infection progression 
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